June 30, 2008

The National Institute of Allergy and Infectious Diseases (NIAID) has announced plans to fund clinical trials aimed at reducing the growing trend of antimicrobial resistance. The clinical trials NIAID has requested closely reflect recommendations IDSA made to the institute last summer.

NIAID is seeking targeted Phase III and Phase IV clinical trials of acute otitis media, pneumonia, urinary tract infections, and bacteremia. The areas of study are proper dosage, length of therapy, and need for therapy.  Up to $63 million is available for the studies.

IDSA has been urging NIAID to increase clinical and translational research on antimicrobial resistance. In a July 2007 letter to NIAID, the Society proposed three targeted clinical trials studying antimicrobial use for otitis media, pneumonia, and cellulitis. NIAID already has funded a trial on cellulitis.

See the IDSA website for more information about the Society’s advocacy efforts addressing the threat of antimicrobial resistance.

 

How useful is this article?